WHO’s Solidarity clinical trial enters new phase

The World Health Organisation (WHO) has announced the next phase in its Solidarity trial. The Solidarity PLUS will enrol hospitalised patients to test three new drugs in hospitalised COVID-19 patients. These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients. They are already used for other indications: artesunate is used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn’s Disease and rheumatoid arthritis. These drugs were donated for the trial by their manufacturers. The Solidarity PLUS trial is a platform trial that represents the largest global collaboration among the WHO Member States. It involves thousands of researchers in over 600 hospitals in 52 countries, 16 more countries than the first phase of trials. This allows the trial to assess multiple treatments at the same time using a single protocol, recruiting thousands of patients to generate robust estimates on the effect a drug may have on mortality, even moderate effects.